Prior studies have highlighted the importance of ICOS in enhancing combination therapy with anti-CTLA-4 treatments [21], as seen in bladder cancer patients in whom ICOS-expressing T cells increased after therapy. Here, ICOS is linked to urinary bladder cancer.